|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
JP2011513427A
(ja)
*
|
2008-03-06 |
2011-04-28 |
ジェネンテック， インコーポレイテッド |
ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
RU2612903C2
(ru)
|
2010-08-02 |
2017-03-13 |
Ридженерон Фармасьютикалз, Инк. |
Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
|
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
EP3264089A1
(en)
|
2010-08-31 |
2018-01-03 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
SG188324A1
(en)
|
2010-09-03 |
2013-04-30 |
Academia Sinica |
Anti-c-met antibody and methods of use thereof
|
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
BR112013023653A2
(pt)
|
2011-03-17 |
2016-12-13 |
Univ Ramot |
anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
|
|
DK2694972T3
(en)
*
|
2011-04-04 |
2017-10-02 |
Pierian Holdings Inc |
PROCEDURES FOR PREVENTING AND IMPROVING GASTRIC CANCER SURVIVAL
|
|
PT2748201T
(pt)
*
|
2011-08-23 |
2018-02-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas que ativam as células t
|
|
KR101886983B1
(ko)
|
2011-08-23 |
2018-08-08 |
로슈 글리카트 아게 |
2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
|
|
JP5925893B2
(ja)
*
|
2011-08-23 |
2016-05-25 |
ロシュ グリクアート アーゲー |
二重特異性抗原結合分子
|
|
WO2013026837A1
(en)
*
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
WO2013033008A2
(en)
*
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
KR20130037153A
(ko)
*
|
2011-10-05 |
2013-04-15 |
삼성전자주식회사 |
항 ｃ-Ｍｅｔ 항체 및 그의 용도
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
GB2504139B
(en)
|
2012-07-20 |
2014-12-31 |
Argen X Bv |
Antibodies to highly conserved targets produced by the immunisation of Camelidae species
|
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
|
KR101963230B1
(ko)
|
2011-12-26 |
2019-03-29 |
삼성전자주식회사 |
복수개의 단일 항체를 포함하는 단백질 복합체
|
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
|
TW201843172A
(zh)
*
|
2012-06-25 |
2018-12-16 |
美商再生元醫藥公司 |
抗－ｅｇｆｒ抗體及其用途
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
JP6581505B2
(ja)
|
2012-10-03 |
2019-09-25 |
ザイムワークス，インコーポレイテッド |
重鎖および軽鎖ポリペプチドの対を定量化する方法
|
|
KR101911438B1
(ko)
|
2012-10-31 |
2018-10-24 |
삼성전자주식회사 |
이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
|
|
EP2914628A1
(en)
*
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
EP2914629A1
(en)
|
2012-11-05 |
2015-09-09 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
PL2922872T3
(pl)
*
|
2012-11-21 |
2019-03-29 |
Janssen Biotech, Inc. |
Bispecyficzne przeciwciała przeciwko egfr/c-met
|
|
KR102545617B1
(ko)
|
2012-11-28 |
2023-06-20 |
자임워크스 비씨 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
RU2015140915A
(ru)
*
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
MX2015011712A
(es)
|
2013-03-06 |
2016-04-04 |
Merrimack Pharmaceuticals Inc |
Anticerpos biespecificos fc en fila anti-c-met.
|
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102049990B1
(ko)
*
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
KR102049991B1
(ko)
*
|
2013-03-28 |
2019-12-02 |
삼성전자주식회사 |
항 c-Met/항 Her2 이중 특이 항체
|
|
KR102067613B1
(ko)
*
|
2013-03-28 |
2020-01-20 |
삼성전자주식회사 |
항 c-Met 항체 및 항 her2 항체를 포함하는 병용 투여용 조성물
|
|
KR102074421B1
(ko)
*
|
2013-03-29 |
2020-02-10 |
삼성전자주식회사 |
항 c-Met/항 EGFR 이중 특이 항체
|
|
US9388243B2
(en)
|
2013-05-29 |
2016-07-12 |
Samsung Electronics Co., Ltd. |
Method of target membrane protein depletion
|
|
KR102190220B1
(ko)
*
|
2013-05-29 |
2020-12-14 |
삼성전자주식회사 |
타겟 특이적 세포막 단백질 제거용 조성물
|
|
US9879081B2
(en)
*
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
KR102236367B1
(ko)
*
|
2013-07-26 |
2021-04-05 |
삼성전자주식회사 |
DARPin을 포함하는 이중 특이 키메라 단백질
|
|
KR102089591B1
(ko)
*
|
2013-07-29 |
2020-03-18 |
삼성전자주식회사 |
항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
IL244623B
(en)
|
2013-10-14 |
2022-08-01 |
Janssen Biotech Inc |
Cysteine engineered fibronectin type iii domain binding molecules
|
|
EA039356B1
(ru)
*
|
2013-10-18 |
2022-01-18 |
Янссен Байотек, Инк. |
БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
|
|
US9717715B2
(en)
|
2013-11-15 |
2017-08-01 |
Samsung Electronics Co., Ltd. |
Method of combination therapy using an anti-C-Met antibody
|
|
CA2924268C
(en)
*
|
2013-11-21 |
2021-05-18 |
F. Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
|
MX376384B
(es)
|
2013-11-27 |
2025-03-07 |
Zymeworks Bc Inc |
Construcciones de union a antigenos biespecificas dirigidas a her2.
|
|
KR102178323B1
(ko)
|
2013-11-29 |
2020-11-13 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
|
US10370692B2
(en)
|
2013-12-20 |
2019-08-06 |
Hoffmann-La Roche Inc. |
Recombinant polypeptide production methods
|
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合ｅｇｆｒ及ｍｅｔ之多功能抗體
|
|
BR112016015589A2
(pt)
*
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
|
KR102194142B1
(ko)
*
|
2014-01-20 |
2020-12-23 |
삼성전자주식회사 |
항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물
|
|
KR20160125965A
(ko)
*
|
2014-02-28 |
2016-11-01 |
아스테라스 세이야쿠 가부시키가이샤 |
신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
|
|
RU2016141307A
(ru)
|
2014-03-21 |
2018-04-24 |
Регенерон Фармасьютикалз, Инк. |
Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
|
|
RU2723940C2
(ru)
*
|
2014-03-21 |
2020-06-18 |
Экс-Боди, Инк. |
Биспецифические антигенсвязывающие полипептиды
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
KR102526945B1
(ko)
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
|
KR102401595B1
(ko)
*
|
2014-05-09 |
2022-05-24 |
삼성전자주식회사 |
항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
|
|
US9975960B2
(en)
*
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
US20170233489A1
(en)
*
|
2014-05-26 |
2017-08-17 |
Samsung Electronics Co., Ltd. |
Composition for combination therapy comprising anti-her2 antibody and anti-c-met antibody
|
|
EA201692476A1
(ru)
|
2014-05-28 |
2017-07-31 |
Займворкс Инк. |
Модифицированные антигенсвязывающие полипептидные конструкции и их применение
|
|
KR102259232B1
(ko)
*
|
2014-08-25 |
2021-05-31 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
|
CN105888672B
(zh)
*
|
2014-09-02 |
2018-07-27 |
北京中煤矿山工程有限公司 |
一种斜冻结孔用外夹式下冻结管装置
|
|
EP3215524B1
(en)
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
CN107074955B
(zh)
|
2014-11-20 |
2021-06-22 |
豪夫迈·罗氏有限公司 |
针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
CN107849137B
(zh)
*
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CA3000869A1
(en)
|
2015-10-08 |
2017-04-13 |
Zymeworks Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
US11235063B2
(en)
|
2015-11-03 |
2022-02-01 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
SG11201811062XA
(en)
|
2016-06-21 |
2019-01-30 |
Janssen Biotech Inc |
Cysteine engineered fibronectin type iii domain binding molecules
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
JP7104703B2
(ja)
|
2016-12-14 |
2022-07-21 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
|
|
WO2018118616A1
(en)
*
|
2016-12-22 |
2018-06-28 |
Eli Lilly And Company |
Methods for producing fabs and igg bispecific antibodies
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
KR102078292B1
(ko)
|
2017-05-30 |
2020-02-19 |
주식회사 종근당 |
신규한 항 c-Met 항체 및 이의 용도
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
WO2019122409A1
(en)
|
2017-12-22 |
2019-06-27 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
US11780926B2
(en)
*
|
2018-03-22 |
2023-10-10 |
Universität Stuttgart |
Multivalent binding molecules
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
IL323061A
(en)
*
|
2018-04-11 |
2025-10-01 |
Inhibrx Biosciences Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
CN112789294A
(zh)
|
2018-07-24 |
2021-05-11 |
印希比股份有限公司 |
含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
KR102239781B1
(ko)
*
|
2019-04-08 |
2021-04-13 |
주식회사 녹십자 |
Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
|
|
BR112021019959A2
(pt)
*
|
2019-04-17 |
2022-02-08 |
Novo Nordisk As |
Anticorpo biespecífico, e, formulação farmacêutica
|
|
KR20220063185A
(ko)
|
2019-09-16 |
2022-05-17 |
리제너론 파마슈티칼스 인코포레이티드 |
면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
|
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
EP4045061A4
(en)
|
2019-10-14 |
2024-04-17 |
ARO Biotherapeutics Company |
FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
JP2024517610A
(ja)
|
2021-04-14 |
2024-04-23 |
アロ・バイオセラピューティクス・カンパニー |
Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
|
|
BR112023021318A2
(pt)
|
2021-04-14 |
2023-12-19 |
Aro Biotherapeutics Company |
Conjugados de domínio fn3-sirna e usos dos mesmos
|
|
WO2023069888A1
(en)
|
2021-10-18 |
2023-04-27 |
Tavotek Biotherapeutics (Hong Kong) Limited |
ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
|
|
CN118742325A
(zh)
|
2022-01-28 |
2024-10-01 |
上海岸阔医药科技有限公司 |
预防或治疗与抗肿瘤剂相关的疾病或病症的方法
|
|
WO2023155905A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海岸阔医药科技有限公司 |
化合物及其用途
|
|
EP4604988A1
(en)
|
2022-10-21 |
2025-08-27 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
JP2025539837A
(ja)
*
|
2022-11-24 |
2025-12-09 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ｈｇｆｒとｅｇｆｒに特異的に結合する二重特異性抗体を含む医薬組成物
|
|
AU2024252640A1
(en)
|
2023-04-07 |
2025-10-02 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
US20240383990A1
(en)
|
2023-04-07 |
2024-11-21 |
Diagonal Therapeutics Inc. |
Hinge-modified bispecific antibodies
|
|
WO2024243048A1
(en)
|
2023-05-19 |
2024-11-28 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to il12 receptor
|
|
TW202502822A
(zh)
*
|
2023-07-07 |
2025-01-16 |
大陸商四川科倫博泰生物醫藥股份有限公司 |
Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
|
|
TW202502823A
(zh)
*
|
2023-07-07 |
2025-01-16 |
大陸商四川科倫博泰生物醫藥股份有限公司 |
Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
|
|
WO2025025434A1
(zh)
*
|
2023-08-02 |
2025-02-06 |
百泰生物药业有限公司 |
EGFR/c-Met双特异性抗体及其应用
|
|
WO2025090519A1
(en)
|
2023-10-23 |
2025-05-01 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
WO2025103450A1
(en)
*
|
2023-11-15 |
2025-05-22 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Antibody-drug conjugates targeting egfr/c-met and preparation methods and uses thereof
|
|
WO2025213061A2
(en)
|
2024-04-04 |
2025-10-09 |
Ethyreal Bio, Inc. |
Anti-tshr antibodies and uses thereof
|